Nvidia reports strong guidance as AI boom sparks ’off the charts’ Blackwell sales
Phillip Frost, CEO and Chairman of OPKO Health, INC. (NASDAQ:OPK), along with Frost Gamma Investments Trust, reported purchasing shares of OPKO Health on November 18, 2025. The purchases totaled $737,747.
The transactions included the acquisition of OPKO Health common stock through several purchases. These purchases were executed at prices ranging from $1.245 to $1.29, with a total value of $678905. Additionally, shares were acquired at a price of $1.26, amounting to $58842.
Following these transactions, the number of shares owned indirectly by Phillip Frost M.D. is 214,966,448. He also directly owns 3,568,951 shares and indirectly owns 30,127,177 shares.
In other recent news, Opko Health reported its financial results for the third quarter of 2025, showing a stronger-than-expected performance. The company achieved a net income of $21.6 million, or $0.03 per share, which exceeded the anticipated loss of $0.06 per share. However, revenue came in at $151.6 million, slightly below the expected $160.78 million. In another development, Jefferies downgraded Opko Health’s stock from Buy to Hold, with a revised price target of $1.60, down from $2.00. This downgrade was attributed to concerns over flat year-over-year sales guidance for Ngenla, a growth hormone product developed in collaboration with Pfizer, projected for 2026. These recent developments highlight the mixed outlook for Opko Health, balancing strong earnings performance with challenges in product sales projections.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.